Dupixent Profits Lift Regeneron Past Wall Street Forecasts
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
Regeneron's revenue grew 36% to $5.12 billion in the third quarter, the drugmaker said Friday.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
2 sources behind this story.